Latest International Markets News

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.

Aspermont’s marketing arm Nexus has secured a key role promoting Timor-Leste’s second mining licensing round, reinforcing its growing influence in global resource sector campaigns.

ClearVue Technologies has secured a $4.6 million capital raise and signed major partnerships, setting the stage for commercialisation in 2026 with a robust $60 million project pipeline.

BPH Global Limited secured $1.1 million in a recent placement and reported robust growth in its Indonesian seaweed operations, alongside promising advances in innovative seaweed-based products and strategic regional partnerships.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Pure Hydrogen Corporation reported strong commercial momentum in the September 2025 quarter, securing multiple hydrogen vehicle orders across Australia and the US, expanding international distribution, and raising fresh capital to fuel growth.

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.